ArticleBreast cancer research and treatment2017
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05951699 (Prospective Clinical Trial to Assess a Mini-invasive Pre-surgical Procedure to Detect Residual Breast or Axillary Disease in Patients With cT1-T2-T3 cN0/N1 Breast Cancer in Complete Clinical/Radiological Remission After Primary Chemotherapy), which is not on this map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Clinical Trial to Assess a Mini-invasive Pre-surgical Procedure to Detect Residual Breast or Axillary Disease in Patients With cT1-T2-T3 cN0/N1 Breast Cancer in Complete Clinical/Radiological Remission After Primary Chemotherapy
Who cites it
70 citing papers in PubMed, 131 citations in OpenAlex.
- Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.Nature communications · 2025Trial
- Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.Annals of surgical oncology · 2023Trial
- The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial.Scientific reports · 2022Trial
- Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.Annals of surgical oncology · 2026Article
- Predictive Value of Routine Imaging for the Diagnosis of Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.Annals of surgical oncology · 2026Article
- Early predictive value of calcification on ultrasound and mammography for pathological complete response to neoadjuvant chemotherapy in breast cancer.BMC women's health · 2026Article
- Pathological response to neoadjuvant chemotherapy and survival in patients with breast cancer: A multicentric retrospective study.Oncology letters · 2026Article
- Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy.Scientific reports · 2026Article
- Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade.Frontiers in oncology · 2026Article
- Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer.NPJ breast cancer · 2025Article
- Morphological analysis of tumor microenvironment in HER2-positive breast cancer: predicting response to neoadjuvant chemotherapy on histopathological images.Breast cancer research : BCR · 2025Article
- Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study.Journal of clinical medicine · 2025Article
- Survival Benefits and Less Intensive Treatment for Women with Early-Stage Breast Cancer Diagnosed While Participating in Population-Based Screening.Annals of surgical oncology · 2025Article
- Article
- Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.Breast cancer research and treatment · 2025Article
- A predictive model for neoadjuvant therapy response in breast cancer.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.NPJ breast cancer · 2025Article
- Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?Irish journal of medical science · 2025Article
- Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features.Frontiers in oncology · 2025Article
- Are the Common Genetic 3'UTR Variants in ADME Genes Playing a Role in Tolerance of Breast Cancer Chemotherapy?International journal of molecular sciences · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological complete response (pCR) is the ultimate response in breast cancer patients treated with neoadjuvant chemotherapy (NCT). It might be a surrogate outcome for disease-free survival (DFS) and overall survival (OS). We studied the effect of clinical tumor stage (cT-stage) on tumor pCR and the effect of pCR per cT-stage on 5-year OS and DFS.
methodsUsing the Netherlands Cancer Registry, all primary invasive breast cancer patients treated with NCT from 2005 until 2008 were identified. Univariable logistic regression analysis was performed to evaluate the effect of cT-stage on pCR, stepwise logistic regression analysis to correct for potential confounders and Kaplan-Meier survival analyses to calculate OS and DFS after five years.
resultsIn 2366 patients, overall pCR rate was 21%. For cT1, cT2, cT3, and cT4, pCR rates were 31, 22, 18, and 17%, respectively. Lower cT-stage (cT1-2 vs cT3-4) was a significant independent predictor of higher pCR rate (p < 0.001, OR 3.15). Furthermore, positive HER2 status (p < 0.001, OR 2.30), negative estrogen receptor status (p = 0.062, OR 1.69), and negative progesterone receptor status (p = 0.008, OR 2.27) were independent predictors of pCR. OS and DFS were up to 20% higher in patients with cT2-4 tumors with pCR versus patients without pCR. DFS was also higher for cT1 tumors with pCR.
conclusionsThe most important predictor of pCR in breast cancer patients is cT-stage: lower cT-stages have significantly higher pCR rates than higher cT-stages. Patients with cT2-4 tumors achieving pCR have higher OS and DFS compared to patients not achieving pCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.